271 related articles for article (PubMed ID: 19514966)
1. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
2. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C; Evrard A; Ciccolini J
J Clin Oncol; 2007 Oct; 25(30):4855; author reply 4855-6. PubMed ID: 17947739
[No Abstract] [Full Text] [Related]
3. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
4. The role of deoxycytidine kinase in gemcitabine cytotoxicity.
van der Wilt CL; Kroep JR; Bergman AM; Loves WJ; Alvarez E; Talianidis I; Eriksson S; van Groeningen CJ; Pinedo HM; Peters GJ
Adv Exp Med Biol; 2000; 486():287-90. PubMed ID: 11783501
[No Abstract] [Full Text] [Related]
5. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
[TBL] [Abstract][Full Text] [Related]
7. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
8. [Clinical pharmacology of nucleoside analogues].
Milano G; Chamorey AL; Thyss A
Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
[TBL] [Abstract][Full Text] [Related]
9. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
11. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett W; Huang P; Searcy CE; Gandhi V
Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
17. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Ueno H; Kiyosawa K; Kaniwa N
Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
[TBL] [Abstract][Full Text] [Related]
19. A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity.
Santos SM; Icyuz M; Pound I; William D; Guo J; McKinney BA; Niederweis M; Rodgers J; Hartman JL
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31575041
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Adv Exp Med Biol; 1994; 370():139-43. PubMed ID: 7660877
[No Abstract] [Full Text] [Related]
[Next] [New Search]